SMITHKLINE KYTRIL, FAMVIR COULD BE DIVESTMENT CANDIDATES IN MERGER WITH GLAXO; MERGER WOULD GIVE GLAXO ENTRY INTO PBM, CLINICAL LABS BUSINESSES
Executive Summary
The proposed merger of SmithKline Beecham and Glaxo Wellcome could open up the anti-herpes and anti-emetic markets to new competitors in the U.S. if product divestitures are required as part of the antitrust review of the merger.